# Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM

> **NCT06543069** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 28 (estimated)

## Conditions studied

- Malignant Peritoneal Mesothelioma, Advanced

## Interventions

- **DRUG:** Sintilimab, Bevacizumab , Pemetrexed , Cisplatin

## Key facts

- **NCT ID:** NCT06543069
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-31
- **Primary completion:** 2026-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06543069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06543069, "Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06543069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*